Mécanisme d’action de Maltofer®
Propriétés physico-chimiques de Maltofer® 1–5
Même si le sulfate de fer entraîne initialement une hausse légèrement plus rapide des réticulocytes, la hausse induite par Maltofer® est comparable après 10 jours. 6
Réduction du pourcentage d’effets indésirables avec Maltofer® (14,9% vs 34,1% avec du sulfate de fer) 11
1. Geisser P et al. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992;42(12):1439–1452.
2. Geisser P und Burckhardt S. The Pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011;3(1):12–33.
3. Sharp P und Kaila S. Molecular mechanisms involved in intestinal iron absorption. World J Gastroenterol 2007; 13(35):4716–4724.
4. Schümann K et al. Differences in circulating non-transferrin-bound iron after oral administration of ferrous sulfate, sodium iron EDTA, or iron polymaltose in women with marginal iron stores. Food Nutr Bull 2013;34(2):185–935.
5. Hentze M et al. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004;117(3):285–297.
6. Borbolla JR et al. Iron hydroxide polymaltose complex vs iron sulphate in the treatment of iron deficiency anaemia in infants. Rev Mex Pediatr 2000; 67: 63–67.
7. Toblli J und Brignoli R. Iron(III)-hydroxide Polymaltose Complex in Iron Deficiency Anemia. Arzneimittelforschung 2007; 57(6A): 431–438.
8. Ortiz R et al. Efficacy and safety of oral iron(III) polymaltose complex versus ferrous sulfate in pregnant women with iron-deficiency anemia: a multicenter, randomized, controlled study. The Journal of Maternal-Fetal and Neonatal Medicine 2011; 24(11): 1347–1352.
9. Jacobs P et al. Oral iron therapy in human subjects: comparative absorption between ferrous salts and iron polymaltose. Journal of medicine 1984;15(5–6):367–377.
10. Kaltwasser JP, Werner E et Niechzial M. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneimittelforschung 987;37(1A):122–129.
11. Lundqvist H und Sjöberg F. Food interaction of oral uptake of iron / a clinical trial using 59 Fe. Arzneimittelforschung 2007; 57(6A): 401–416.
12. Geisser P. Safety and efficacy of iron(III)-hydroxide polymaltose complex / a review of over 25 years’ experience. Arzneimittelforschung 2007; 57: 439–452.
13. Kaltwasser JP et al. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneimittelforschung 1987; 37(1A): 122–129.
14. Selon les informations professionnelles Maltofer® et Maltofer Fol®: www.swissmedicinfo.ch.
15. Yasa B et al. Efficacy, tolerability, and acceptability of iron hydroxide polymaltose complex versus ferrous sulfate: A randomized trial in pediatric patients with iron deficiency anemia. Int J Pediatr 2011; 2011: 524–520.
16. Walter T et al. Tolerance and acceptability in infants of iron polymaltose complex. Ars Medici 2005; 9: 428–431.
17. Andrade JVD. Treatment of iron deficiency anaemia with iron-hydroxide polymaltose complex. ARP-Supl Arq Bras Med 1992; 66: 253–258.
Les professionnels de la santé peuvent exiger de Vifor Pharma Switzerland SA une copie intégrale des références citées. Informations professionnelles Maltofer®: www.swissmedicinfo.ch.